TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24355824

Group type: EXPERIMENTAL
Intervention: Isometric exercise (2 minutes of hand-gripping)
Number of subjects: 21
Study: 24355920

Group type: EXPERIMENTAL
Intervention: Intravenous mangafodipir
Number of subjects: 23
Study: 24356046

Group type: EXPERIMENTAL
Intervention: INCRAFT® Stent-Graft System
Number of subjects: 60
Study: 24356623

Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg orally daily (maximally tolerated dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Erlotinib added to infusional 5-FU 225 mg/M2/day, bevacizumab 5 mg/kg, and radiation 50.4 Gy in 28 fractions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Erlotinib added to infusional 5-FU, bevacizumab and radiation
Number of subjects: 32
Study: 24356628

Group type: EXPERIMENTAL
Intervention: High p-AKT expression group
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: High p-AKT expression group with concurrent Epstein-Barr virus positivity
Number of subjects: 262

Group type: COMPARATOR
Intervention: Low p-AKT expression group
Number of subjects: 262
Study: 24356787

Group type: EXPERIMENTAL
Intervention: PHiD-CV booster dose co-administered with DTPa booster dose
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 2-dose catch-up with PHiD-CV (first dose co-administered with DTPa booster dose)
Number of subjects: 104
Study: 24358067

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 4484

Group type: COMPARATOR
Intervention: Diclofenac SR 75 mg twice daily plus omeprazole 20 mg daily
Number of subjects: 4484
Study: 24358863

Group type: EXPERIMENTAL
Intervention: Low pain threshold group
Number of subjects: 40
Study: 24359231

Group type: EXPERIMENTAL
Intervention: Dutch version of the Western Ontario Rotator Cuff Index (WORC)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dutch WORC
Number of subjects: 57
Study: 24359243

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study: 24359635

Group type: EXPERIMENTAL
Intervention: New antipsychotic monotherapy treatment initiated within 2 weeks prior to enrollment
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: New antipsychotic monotherapy treatment
Number of subjects: 568
Study: 24359972

Group type: EXPERIMENTAL
Intervention: Group 2 (max CGM glucose value ≥ 11 mmol/l)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Group 1 (max CGM glucose value < 11 mmol/l)
Number of subjects: 38
Study: 24360325

Group type: EXPERIMENTAL
Intervention: CD49d-expressing neutrophils
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24360599

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment (20-40 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluoxetine nonresponders
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 16
Study: 24360789

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment, mean final dose 0.6 (0.25) mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 39
Study: 24360866

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24360992

Group type: EXPERIMENTAL
Intervention: Mildly elevated ALT
Number of subjects: 91

Group type: COMPARATOR
Intervention: Normal ALT
Number of subjects: 91

Group type: COMPARATOR
Intervention: Elevated ALT
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall biopsy analysis
Number of subjects: 91
Study: 24361681

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir monotherapy (MtDRV/rtv)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Virological failure episodes
Number of subjects: 144

Group type: COMPARATOR
Intervention: Adherence less than 95%
Number of subjects: 144

Group type: COMPARATOR
Intervention: Basal proviral DNA levels more than 2 log10 copies/10 PBMCs
Number of subjects: 144
Study: 24361682

Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 24362550

Group type: EXPERIMENTAL
Intervention: Triapine (105 mg/m²/day) followed by fludarabine (30 mg/m²/day) daily for 5 consecutive days
Number of subjects: 37
Study: 24363672

Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal with Papacarie gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Removal of carious dentin with low-speed bur (Control Group)
Number of subjects: 20
Study: 24363760

Group type: EXPERIMENTAL
Intervention: TPN (Total Parenteral Nutrition)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral arginine, peripheral TPN
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TPN preoperatively
Number of subjects: 51

Group type: COMPARATOR
Intervention: Without nutrition (control group)
Number of subjects: 51
Study: 24363954

Group type: EXPERIMENTAL
Intervention: real-rTMS
Number of subjects: 11

Group type: COMPARATOR
Intervention: sham-rTMS
Number of subjects: 11
Study: 24363955

Group type: EXPERIMENTAL
Intervention: Successful Group (SG)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Less Successful Group (LSG)
Number of subjects: 61
Study: 24365086

Group type: EXPERIMENTAL
Intervention: Standard diet (33% fat, 52% carbohydrate, 15% protein) for 7 days followed by a test meal (40% fat, 40% carbohydrate, 20% protein) on Day 8.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Race, SI, VAT and apolipoproteins in random effects models (REM).
Number of subjects: 31
Study: 24365862

Group type: EXPERIMENTAL
Intervention: Trauma male patients
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Trauma female patients
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Nontrauma male patients
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Nontrauma female patients
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Trauma patients
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Men (general)
Number of subjects: 2291
Study: 24366423

Group type: EXPERIMENTAL
Intervention: Erythritol 36 g/day as an orange-flavored beverage for 4 weeks
Number of subjects: 24
Study: 24366583

Group type: EXPERIMENTAL
Intervention: Melatonin (4 mg) twice daily until birth
Number of subjects: 12
Study: 24366929

Group type: EXPERIMENTAL
Intervention: Pain management
Number of subjects: 3106

Group type: EXPERIMENTAL
Intervention: Inadequate pain management
Number of subjects: 3106

Group type: EXPERIMENTAL
Intervention: Lower baseline pain level
Number of subjects: 3106

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 3106

Group type: EXPERIMENTAL
Intervention: Poor health status
Number of subjects: 3106
Study: 24367599

Group type: EXPERIMENTAL
Intervention: Raltegravir, tenofovir disoproxil fumarate, and emtricitabine
Number of subjects: 39
Study: 24367942

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 30
Study: 24368064

Group type: EXPERIMENTAL
Intervention: Twice-weekly gemcitabine (starting dose 15 mg/m², escalated to 20, 25, and 30 mg/m²) and cisplatin (CDDP 20 mg/m²/day over 4 days every 21 days) with concomitant radiation therapy (63 Gy in 1.8 fractions)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Twice-weekly gemcitabine (30 mg/m²)
Number of subjects: 14
Study: 24368985

Group type: EXPERIMENTAL
Intervention: SILS cholecystectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: TPCL cholecystectomy
Number of subjects: 100
Study: 24369044

Group type: EXPERIMENTAL
Intervention: Strong SOC (score 0-1)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Weak SOC (score 2-6)
Number of subjects: 250
Study: 24369057

Group type: EXPERIMENTAL
Intervention: Pneumatic device (Nosten®) for continuous control of cuff pressure (Pcuff) for 24 hours
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine care of cuff pressure using a manometer for 24 hours
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pneumatic device (Nosten®) for continuous control of cuff pressure (Pcuff)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Continuous control of Pcuff
Number of subjects: 64
Study: 24369094

Group type: EXPERIMENTAL
Intervention: Belinostat (PXD101) administered intravenously at a dose of 1000 mg/m² daily on days 1-5 of a 21-day cycle until progression or unacceptable toxicity.
Number of subjects: 12
Study: 24369412

Group type: EXPERIMENTAL
Intervention: 40 mg adalimumab every other week
Number of subjects: 41
Study: 24369764

Group type: EXPERIMENTAL
Intervention: Exenatide twice daily (BID)
Number of subjects: 2388

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 2388
Study: 24370210

Group type: EXPERIMENTAL
Intervention: Vinorelbine and sorafenib (MTD)
Number of subjects: 41
Study: 24371246

Group type: EXPERIMENTAL
Intervention: Expanded Quantitative Urine Culture (EQUC) protocol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard urine culture protocol
Number of subjects: 65
Study: 24372730

Group type: EXPERIMENTAL
Intervention: Salvage partial low-dose rate brachytherapy
Number of subjects: 616

Group type: COMPARATOR
Intervention: Initial low-dose rate brachytherapy
Number of subjects: 616
Study: 24373120

Group type: EXPERIMENTAL
Intervention: Caspofungin + voriconazole
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Caspofungin + liposomal amphotericin B (L-AmB)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination therapy (combo)
Number of subjects: 84
Study: 24373343

Group type: EXPERIMENTAL
Intervention: Hormone therapy (estrogen-alone and estrogen plus progestin)
Number of subjects: 720
Study: 24373573

Group type: EXPERIMENTAL
Intervention: Elective surgeries (various types)
Number of subjects: 2397

Group type: EXPERIMENTAL
Intervention: Positive Douleur Neuropathique 4 Questions (DN4)
Number of subjects: 2397

Group type: EXPERIMENTAL
Intervention: Time since surgery
Number of subjects: 2397

Group type: EXPERIMENTAL
Intervention: Older age and low anxiety score
Number of subjects: 2397

Group type: EXPERIMENTAL
Intervention: Recent negative event, low preoperative quality of life, previous history of peripheral neuropathy
Number of subjects: 2397

Group type: COMPARATOR
Intervention: Type of anesthesia
Number of subjects: 2397
Study: 24373580

Group type: EXPERIMENTAL
Intervention: High plasma YKL-40 (concentration higher than the 75th percentile for age-matched healthy subjects)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Normal plasma YKL-40 levels
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: YKL-40 levels
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Severe COPD
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Very severe COPD
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Neutrophil granulocyte count
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Smoking history of > 40 years
Number of subjects: 493
Study: 24373638

Group type: EXPERIMENTAL
Intervention: Emergency radiotherapy (RT) started within 12 hours after onset of neurological symptoms.
Number of subjects: 10
Study: 24374423

Group type: EXPERIMENTAL
Intervention: Medically treated
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgically treated
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgery (banding)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgery (sleeve gastrectomy)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgery (gastric bypass)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Wait-listed
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 500
Study: 24374547

Group type: EXPERIMENTAL
Intervention: Biologic meshes
Number of subjects: 40
Study: 24374856

Group type: COMPARATOR
Intervention: 1,000 mg abiraterone acetate (tablet)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 125 mg and 2,000 mg abiraterone acetate (suspension)
Number of subjects: 16
Study: 24375324

Group type: EXPERIMENTAL
Intervention: Bioavailable testosterone (BioT)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Waist and subcutaneous adipose tissue (SAT)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Waist
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 598
Study: 24376516

Group type: EXPERIMENTAL
Intervention: Self-lavaging device (Delphi Screener™) for cytology and HPV testing
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Self-lavaging device (Delphi Screener™) for HPV testing
Number of subjects: 198
Study: 24376864

Group type: EXPERIMENTAL
Intervention: Detection of Aggregatibacter actinomycetemcomitans (Aa)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aa-non-detected sites
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LPS-stimulated blood samples
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E.coli LPS stimulation of peripheral blood cells from Aa-detected sites
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clinical parameters and serum LPS levels
Number of subjects: 30
Study: 24377099

Group type: EXPERIMENTAL
Intervention: Peptide vaccine in Montanide adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peptide vaccine in Montanide adjuvant with GM-CSF
Number of subjects: 0
Study: 24378417

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/day by mouth for up to 12 months, with possible dose escalation to 600 mg/day at 3 months if stable.
Number of subjects: 30
Study: 24378877

Group type: EXPERIMENTAL
Intervention: SCS+HIPEC (laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: HIPEC treatment with cisplatin at 75 mg/m(2) or oxaliplatin 460 mg/m(2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: SCS+HIPEC
Number of subjects: 84
Study: 24379526

Group type: EXPERIMENTAL
Intervention: Patients with secondary ERMs after PDR
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (patients with idiopathic ERMs)
Number of subjects: 17
Study: 24379928

Group type: EXPERIMENTAL
Intervention: Add-on extended release nicotinic acid (ER-NA)/laropiprant (LRPT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rosuvastatin monotherapy (40 mg/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Add-on micronised fenofibrate
Number of subjects: 100
Study: 24380752

Group type: EXPERIMENTAL
Intervention: drug-targeting nebulization
Number of subjects: 0
Study: 24381190

Group type: EXPERIMENTAL
Intervention: 400 μg of salbutamol
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: F(ENO) measurement
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator FEV1
Number of subjects: 405
Study: 24381226

Group type: EXPERIMENTAL
Intervention: Otlertuzumab administered intravenously, ranging from 0.03 to 20 mg/kg in dose-escalation phase and 10 to 30 mg/kg in dose-expansion phase, weekly for up to 8 weeks followed by 1 dose per month for 4 months.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Otlertuzumab
Number of subjects: 83
Study: 24381750

Group type: EXPERIMENTAL
Intervention: Visceral fat measurement by ultrasound
Number of subjects: 165
Study: 24382963

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 24383474

Group type: EXPERIMENTAL
Intervention: Genetic analysis for percent emphysema in or near SNRPF (rs7957346)
Number of subjects: 7914

Group type: EXPERIMENTAL
Intervention: Genetic analysis for percent emphysema in or near PPT2 (rs10947233)
Number of subjects: 7914

Group type: EXPERIMENTAL
Intervention: Genetic analysis for upper-lower lobe ratio near MAN2B1 (rs10411619) among Hispanics
Number of subjects: 7914

Group type: EXPERIMENTAL
Intervention: Genetic analysis for upper-lower lobe ratio near DHX15 (rs7698250) among Chinese
Number of subjects: 7914

Group type: EXPERIMENTAL
Intervention: Genetic analysis for upper-lower lobe ratio near MGAT5B (rs7221059) among Chinese
Number of subjects: 7914

Group type: EXPERIMENTAL
Intervention: Genetic analysis for percent emphysema near MAN1C1 (rs12130495) among African Americans
Number of subjects: 7914
Study: 24383664

Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation (220 mg per capsule, 2 capsules per day for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fertile controls (no treatment)
Number of subjects: 60
Study: 24383821

Group type: EXPERIMENTAL
Intervention: AposTherapy (non-invasive biomechanical foot-worn device)
Number of subjects: 58
Study: 24383844

Group type: EXPERIMENTAL
Intervention: Unsuccessful cytogenetic analysis (UC)
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Successful cytogenetic analysis
Number of subjects: 1497
Study: 24384108

Group type: EXPERIMENTAL
Intervention: 14-day adhesive patch monitor
Number of subjects: 146

Group type: COMPARATOR
Intervention: 24-hour Holter monitor
Number of subjects: 146
Study: 24384290

Group type: EXPERIMENTAL
Intervention: Subacute ST
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Late/very late ST
Number of subjects: 46
Study: 24384417

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: APACHE III score
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: SAPS II score
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: MODS score
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Underlying lung diseases, serum albumin, serum creatinine, number of organ failures
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: APACHE II and MODS systems
Number of subjects: 197
Study: 24384609

Group type: EXPERIMENTAL
Intervention: Budesonide 1,500 μg
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Budesonide 1,500 μg (in cases with high baseline clinical score ≥13)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo (in cases with high baseline clinical score ≥13)
Number of subjects: 906
Study: 24385027

Group type: EXPERIMENTAL
Intervention: Linezolid + Vitamin B6 (CTG)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Linezolid only (LTG)
Number of subjects: 75
Study: 24385474

Group type: EXPERIMENTAL
Intervention: 12-hour training course (4 meetings of 3 hours each in 1 month) for community health workers
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 12-hour training course
Number of subjects: 65
Study: 24385516

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (B6) administered orally starting at 5 mg/kg body weight per day, increasing by 5 mg/kg every 6 weeks up to 20 mg/kg per day at week 24.
Number of subjects: 12
Study: 24386229

Group type: EXPERIMENTAL
Intervention: Blood culture introduction
Number of subjects: 258
Study: 24386300

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 400/12 µg twice a day for 4 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 37
Study: 24386357

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 1060
Study: 24387695

Group type: EXPERIMENTAL
Intervention: MK-2206 45 mg QOD with carboplatin (AUC 6.0) and paclitaxel 200 mg/m2
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MK-2206 200 mg Q3W with docetaxel 75 mg/m2
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MK-2206 135 mg QW with erlotinib 100 or 150 mg daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MK-2206 (various doses)
Number of subjects: 72
Study: 24388030

Group type: EXPERIMENTAL
Intervention: Therapeutic manipulation targeting newly identified cellular and molecular targets in liver regeneration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preclinical models of liver injury.
Number of subjects: 0
Study: 24388161

Group type: EXPERIMENTAL
Intervention: Follow-up after 4-8 weeks
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Patients who returned for follow-up
Number of subjects: 539

Group type: COMPARATOR
Intervention: Patients who did not return for follow-up
Number of subjects: 539
Study: 24388292

Group type: EXPERIMENTAL
Intervention: Web-based intervention (action plan)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Paper-based intervention (persuasive communication)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Web-based IME methodology
Number of subjects: 270
Study: 24388332

Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood (UCB) cells, up to 4 doses adjusted for volume and red blood cell content, 1-5 × 10(7) cells/dose
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cooled infants without available cells (control group)
Number of subjects: 23
Study: 24388695

Group type: EXPERIMENTAL
Intervention: 0.75 mg levonorgestrel (LNG) taken shortly after sex
Number of subjects: 72
Study: 24389297

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg administered subcutaneously at baseline, week 4, and week 16
Number of subjects: 20
Study: 24389906

Group type: EXPERIMENTAL
Intervention: CsA concentration at C4
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TAC concentration at C0 or C2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: C0 for TAC monitoring
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: C0 with CsA
Number of subjects: 50
Study: 24392226

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 0
Study: 24392948

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 0
Study: 24393402

Group type: EXPERIMENTAL
Intervention: Exercise (graded physical stress test)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control subjects (no exercise intervention)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: T2DM patients (exercise intervention)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Healthy female individuals (exercise intervention)
Number of subjects: 87
Study: 24393475

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 9161

Group type: EXPERIMENTAL
Intervention: Subjects aged <60 years
Number of subjects: 9161

Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 9161

Group type: EXPERIMENTAL
Intervention: Higher fasting glucose levels (6.39±0.49 vs 6.24±0.43 mmol/L)
Number of subjects: 9161

Group type: EXPERIMENTAL
Intervention: Overall IFG subjects
Number of subjects: 9161
Study: 24394678

Group type: EXPERIMENTAL
Intervention: Sexting behavior (sending sexually explicit messages and/or pictures)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Sexting behavior (sending photos)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Sexting behavior (sending text messages)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Sexting behavior (both photo and text messages)
Number of subjects: 322
Study: 24395025

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of TIV and PCV13
Number of subjects: 530

Group type: COMPARATOR
Intervention: TIV alone
Number of subjects: 530

Group type: COMPARATOR
Intervention: PCV13 alone
Number of subjects: 530